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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that usually affects 
but not limited to the elder population. We see that when an individual develops AD, the brain 
cells are degenerating and dying at rates that are uncontrollable. Worldwide AD has affected at 
least 50 million people and we will continue to see this number increase. Although the research 
done on AD has made great strides, much is still unknown and being studied. Previous studies 
have allowed us to understand that many of the impacts of AD are correlated to various regions 
of the brain experiencing atrophy. This causes an individual’s cognitive, behavioral, and social 
skills to be impaired. This paper examined the question of how the use of structural magnetic 
resonance imaging (MRI) can be used for studying brain atrophy in AD. Using the software, 
FreeSurfer, we estimated the cortical volumes of various brain regions in AD patients (n = 42) 
and subjects without AD (n = 38). We found  that compared to non-demented individuals, 
demented patients experience more atrophy in multiple brain regions such as the cerebral cortex 
gray and white matter of entorhinal, parahippocampal, fusiform, insula, inferior temporal, 
superior temporal, rostral middle frontal, and lateral occipital gyri, as well as subcortical 
structures, such as amygdala and hippocampus.. Although the sample used was relatively small, 
we expect that using structural MRI scans of larger samples will increase the ability to rely on 
volumetric data to help us further understand what regions are being impacted by AD and 




















Dementia and its Cause: 
In the United States, neurodegenerative diseases affect an estimated 5.3 million people, 
most patients being over the age of 65. Dementia incidence increases exponentially between ages 
of 65 and 90 years and doubles approximately every 5 years (Corrada et al. 2010). Multiple 
pathological processes can lead to neurodegeneration, but the condition itself involves neurons in 
the brain losing function over time and eventually dying. The brain is made up of billions of 
neurons; each of them have a unique structure and function, and they form synapses with other 
neurons. The communication between neurons allow us to do daily things like thinking, moving, 
and talking. Dementia is a clinical syndrome that often results from a neurodegenerative disease 
process. It is a condition that causes loss of memory, language, problem-solving, and other 
thinking abilities. There are millions of individuals living with dementia and it is predicted that 
by 2050 it will continue to increase to 152 million (Livingston et al. 2020).  The most common 
forms of dementia are AD, Lewy body dementia, and vascular brain injury. The severity of the 
disease will differ depending on the individual, but it can be as severe as losing all of one’s 
cognitive abilities and ability to function independently in daily life.  Doctors and researchers 
today still do not fully understand all pathological processes that can lead to dementia. Early 
prevention, diagnosis, and a cure are key focuses in dementia research. Understanding the 
different type of neurodegenerative diseases, processes that occurs during certain stages of the 
diseases, and the effect on the brain are critical to finding a cure, supporting early diagnosis, and 
developing preventative measures.  
The most common type of dementia is AD. This is a progressive and irreversible disease 
that causes the symptoms of dementia to gradually worsen over time. Studies have shown that 





this brain disorder typically occurs after the age of 65 (Bature et. al 2017). This disease causes 
brain atrophy and loss of synaptic connections between networks of neurons. The pathological 
hallmarks of AD contain neuritic plaques, consisting mainly of a pathological protein, amyloid β 
(A𝛽) and neurofibrillary tangles (NFTs), which are intraneuronal deposits of pathologically 
phosphorylated form of microtubule protein tau. A𝛽 accumulation between nerve cells is toxic to 
the surrounding cells, causes inflammation, and disrupts cell function. NFTs form inside neurons 
and disrupt axonal trafficking and other cell functions, and cause difficulty with synaptic 
communication between neurons.   
Even though AD is a neuropathological diagnosis and cannot be made based on clinical 
symptoms, there are some correlations between clinical findings and pathology. There are three 
different stages of AD: mild, moderate, and severe. During the mild stage of AD, the individual 
is able to function normally with some symptoms. Some specific signs of mild AD are 
difficulties with coming up with the right word or name, remembering names when introduced to 
new people, having difficulty performing tasks in social or work settings, forgetting material that 
was just read, losing or misplacing a valuable object, and experiencing increased trouble with 
planning or organizing (Stages of Alzheimer's). The symptoms are not very apparent, and special 
neuropsychological testing is required for diagnosis of cognitive impairment during this stage.  
During the moderate stage of AD, individuals experience greater struggles to perform daily life 
compared to the individuals with mild AD. This stage is the usually the longest stage, requires 
more care, and the symptoms are more pronounced. Although symptoms vary from individual to 
individual, common symptoms that arise during this stage of AD are being forgetful of events or 
personal history, feeling moody or withdrawn, being unable to recall information about 
themselves like their address or telephone number and the school they attended, experiencing 





confusion about where they are or what day it is, requiring help choosing proper clothing for the 
season or the occasion, having trouble controlling their bladder and bowels, experiencing 
changes in sleep patterns, showing an increased tendency to wander or become lost, and 
demonstrating personality and behavioral changes (Stages of Alzheimer's). Lastly, during the 
severe stage of AD, which is the final stage and is very hard for the patient and their caregivers. 
Common symptoms during this stage are the need for around-the-clock assistance with daily 
personal care, losing awareness of recent experiences as well as of their surroundings, 
experiencing changes in physical abilities like walking, sitting, and swallowing, difficulty with 
communication, and becoming vulnerable to infections, especially pneumonia (Stages of 
Alzheimer's). The individual is incapable of almost all tasks, abilities, and skills on their own and 
there are currently no measures to help them get better. There are very limited to no solutions to 
help with progression and the symptoms.   
Another neurodegenerative disease that causes dementia is Lewy body disease (LBD). 
This disease is characterized by presence of Lewy bodies, which are intracellular deposits of a 
pathological form of synaptic protein α-synuclein. α-synuclein deposition causes neuronal 
dysfunction and eventually death. One type of LBD is Parkinson’s disease. In Parkinson’s 
disease, Lewy body formation begins in brainstem, and initially leads to motor impairment, but 
the process can eventually reach cerebral cortex and cause dementia. Another common type of 
LBD is Lewy body dementia, a form of dementia that results from the development of Lewy 
bodies in nerve cells in cerebral cortex. Like AD, LBD has various stages that describe the 
symptoms of the disease over time.  There are seven stages of Lewy Body dementia which are 
referred as: no cognitive decline, very mild cognitive decline, mild cognitive decline, moderate 
cognitive decline, moderately severe cognitive decline, severe cognitive decline, and very severe 





cognitive decline. Similar to AD as the stages progress, the symptoms get worse and the patients 
need more assistance and lose more abilities functionally and mentally. Some key clinical 
features of Lewy body dementia are postural instability, repeated falls, syncope or other transient 
episodes of unresponsiveness, severe autonomic dysfunction, hallucinations, systematized 
delusions, apathy, and anxiety and depression (Outeiro et al. 2019). Unlike AD, there is less 
memory impairment and the difficulty occur more often with visuospatial, attentional, and 
frontal executive functions (Donaghy and McKeith 2014).  
Lastly, vascular brain injury is a result of age-associated pathology in large cerebral 
arteries as well as smaller vessels which is a potential risk factor for cognitive decline and 
dementia in older individuals (Scuteri et al. 2011). A type of vascular brain injury is 
microvascular brain injury (µVBI), and what occurs is that blood flow in large vessels are mostly 
impaired and a development of pathology in small blood vessels (arterioles). µVBI does not 
cause large strokes, but histological examination of the brain shows many small lesions that are 
less than 5mm in the cerebral cortex and subcortical structures. Due to impairment in blood 
transportation to the brain, it can lead to problems with reasoning, planning, judgement, memory, 
and other cognitive abilities. People diagnosed with vascular dementia tend to live four around 
five years after diagnosis, which is less than the average life span for patients with AD (Strand et 
al. 2018). Both vascular brain injury and LBD are known causes of dementia, but AD is the main 
focus of study since it has and still affects so many individuals.  
 
Alzheimer’s Disease 
For many years, much research has been done hoping to a cure for Alzheimer’s disease 
(AD) and related dementias. Although the cure of AD has not yet been discovered, the 





advancement of modern medicine and research have accelerated ways to combat symptoms for a 
short period of time. AD symptoms vary among patients, but symptoms continue to worsen over 
time. Currently, there are two U.S. Food and Drug Administration (FDA) approved medications 
that treat the cognitive symptoms of AD: cholinesterase inhibitors and memantine, which is a 
NDMA receptor antagonist (Medications for Memory). These medications are used to treat 
symptoms such as memory loss, confusion, and problems with thinking and reasoning. When 
focusing on the effects of medications to help with the disease, it is critical to understand how the 
brain is changing volumetrically and pathologically. The brain will decrease volumetrically when 
diagnosed with this disease because the pathology causes the death and decrease of neurons. 
Cerebral atrophy has a strong correlation with cognitive decline (Johnson et al. 2012). 
  The imaging technique called magnetic resonance imaging (MRI) provides detailed 
structural images of the brain that help us assess the volume its regions. Using the volumetric 
data from the MRI, scientists are able to examine which regions of the brain experience atrophy 
during the progression of AD. Structural MRIs provides a technique to understand the disease in 
living and non-living individuals. MRIs are uncommonly performed on post-mortem brains 
because MRIs are costly, we do not see this type of imaging done close to death. But the 
information it provides will be particularly important for understanding the stages of AD by 
providing correlation with autopsy finding. Autopsies are the only technique to confirm the 
diagnoses of the disease.  
 
Techniques to diagnose possible AD during life: 
If AD is suspected, information on an individual’s health changes are inquired, which 
includes types of medication the individual is taking, their diet, alcohol use, any previous 





medical health issues, and any psychological changes. When evaluating the psychological 
changes, they want to see if there are any recognizable changes in their behavior, personality, 
and cognitive ability. To test their cognitive ability, a Mini-Mental State Exam (MMSE) can be 
given to test orientation, attention, memory, language, and visual spatial skills.  The MMSE is a 
short screening tool that provides an overall measure of cognitive impairment in clinical, 
research, and community settings (Arevalo-Rodriguez et al. 2015). The highest score that can be 
achieved is a 30, a score 24-20 indicates mild dementia, 20-13 is considered moderated 
dementia, and 13 and below suggests severe dementia. Another test often used is the Mini-Cog 
test, which is a brief cognitive screening test that consist of two components, a delayed three-
word recall and the clock drawing test (Borson et. al 2005). This is not a diagnostic test for AD 
or any other forms of dementia but assesses cognition. A total score under 5 indicates the 
likelihood of dementia. Additionally to the cognitive tests, laboratory tests such as blood count, 
blood glucose, urinalysis, cerebrospinal fluid, and analysis of the thyroid function can help 
exclude other potential causes of dementia and indirectly confirm the diagnosis of suspected AD. 
Next, a neurological exam is used to rule out any other conditions similar to AD. This exam tests 
the patient’s reflexes, coordination, muscle tone and strength, eye movement, speech, and 
sensation. Lastly, brain imaging is another method to diagnose brain changes suggestive of AD.  
Different brain imaging techniques that can help with diagnosis are computed tomography (CT), 
structural and functional MRI, and positron emission tomography (PET). These different types of 
brain scans allow doctors to find any identifiable characteristics of AD, like amyloid plaques, 
and identify other medical problems like strokes or tumors, which are also cause of dementia.  
There are two common types of MRI, one provides detailed images of organs and tissues 
in the brain (structural MRI) and the other measures the brain activity by looking at blood flow 





in the brain (functional MRI). Structural MRIs provide the shape and size of cortical regions, 
which can provide information about the cumulative neuronal damage which is in turn 
responsible for the clinical state. Previous research has shown that structural MRI is an effective 
noninvasive technique that provides excellent spatial resolution and good contrast. The images 
provide information about the size of brain areas and brain atrophy and therefore, the extent of 
the neurodegeneration can be identified (Lama et al. 2017). MRI scans are expensive and are 
usually performed if there is a specific reason for doing so like a fall or suspected tumor or 
stroke.  Although MRI is expensive it could be very useful to monitor the progression of the 
disease by revisiting the volume of the affected regions, to allow for comparisons with previous 
images.  
MRI could provide some insight in the early stages of AD. Early diagnosis is very 
important because it allows patients to make lifestyle changes that slow down the disease. There 
are many medical conditions and lifestyle factors that increase the chance of cognitive 
impairment and AD. Possible ways to prevent or delay the development of AD are controlling 
hypertension, smoking, obesity, and diabetes. Additionally, mental health disorders like 
depression and infrequent participation in stimulating activities are factors that increase the 
chance of mild cognitive impairment (MCI) and AD (Rasmussen and Langerman 2019). Many 
individuals in the world experience these factors increasing the chance of AD, so it is especially 
important for doctors to pay attention to warning signs of AD. Previous finding based on 
imaging data has shown that there is a long preclinical and presymptomatic period where the 
pathological effects of AD are detectable (Johnson et al. 2012). Using MRI for examining certain 
brain regions is extremely helpful in understanding the disease, as brain regions showing most 





significant rates of atrophy alter as the disease advances, and regional atrophy is already 
occurring long before the onset of symptoms (Scahill et al 2002).  
 
Brain Regions and their Functions 
 In this study, the parts of the brain that were being evaluated were the cerebral cortex 
gray and white matter of entorhinal, parahippocampal, fusiform, insula, inferior temporal, 
superior temporal, rostral middle frontal, and lateral occipital gyri, as well as subcortical 
structures, such as amygdala and hippocampus. The gray and white matter are the tissues that 
make up the central nervous system. These are where the cell bodies, dendrites, axon terminals, 
synapses, axons, and myelin are located. The gray matter contains cell bodies, dendrites and 
axon terminal, which is a major component of the central nervous system.  White matter is 
composed of nerve fibers that connect neurons to other neurons in different brain regions (Fields 
2011).  
There are four lobes in the human brain: frontal lobe, temporal lobe, parietal lobe, and 
occipital lobe. The regions that were examined were part of three of the major lobes in the brain. 
The frontal lobe is the largest of all four lobes; it is important for voluntary movement, 
expressive language, and for managing higher level executive functions. In the frontal lobe, you 
can find the premotor cortex, primary motor cortex, and Broca’s area, which is responsible for 
speech production. The temporal lobe is part of the brain near the brain stem and the cerebellum. 
It is responsible for emotions, smelling, tasting, perception, memory, and understanding 
language. This lobe contains the amygdala, hippocampus, hippocampal regions, and Wernicke’s 
area, which is responsible for speech comprehension. The function of the amygdala allows 
individuals to feel certain emotions, like fear. Amygdala atrophy in AD was prominent in later 





stages and is related to the severity of cognitive impairment (Poulin et al. 2011).  The parietal 
lobe is responsible for sensation and perception and the integration and interpretation of sensory 
information. So, functions such as pain interpretation, visual perception, spatial orientation, and 
speech are located here.  Lastly, the occipital lobe is known as the visual processing center. The 
function of the lobe is to control vision and its aspects like distance and depth perception, color 
determination, and facial recognition. The occipital lobe contains the primary visual cortex, 
which is responsible for processing visual stimuli and assessing the intensity, shape, size and 
location of objects in the visual fields (Cechetto and Topolovec 2002). In this study we focused 
on regions which has been shown or are suspected to undergo atrophy in dementia patients at 
different stage of AD.   
 
Ex vivo imaging of the Brain 
  
 Ex-vivo imaging is an uncommon technique, in which the brain is imaged post-mortem, 
and can be very helpful for studying AD and other neurodegenerative diseases. The information 
it provides is important because it can help correlate MRI findings with diagnoses. MRI picture 
of the brain from a person suffering from AD dementia looks very different from a not demented 
brain (Figure 1). The diseased brain has lost a substantial amount of volume in several regions, 
including the hippocampus, amygdala, and regions in the temporal lobes. These regions are 
important for learning and memory, experiencing emotion, and encoding memory, and their loss 
can explain the loss of corresponding abilities in thinking, movement, learning, memory, and 
more.  






Figure 1. Comparison between a healthy brain and a brain of a n individual with AD. MRI of 
healthy brain (left) and MRI of Alzheimer’s brain (right). Yellow square is displaying the cortex, 
blue square is displaying the ventricles, and purple square is displaying the hippocampus. 
(Copyright 2017 by IEEE Institute of Electrical and Electronics Engineers). 
Like mentioned before, when an individual is diagnosed with AD, their brain will usually 
contain A𝛽 -rich neuritic plaques and NFTs, which is accompanied by neuronal death and loss of 
synapses (Kocachan and Dogan 2017). A𝛽 plaques usually appear in the neocortex in the 
beginning and we will see it present in other regions of the brain as the disease progresses. In 
order to track the AD neuropathologic change, there is a ranking system that uses three 
parameters: A𝛽 plaque score, NFT stage, and neuritic plaque score (Hyman et al. 2012)  A𝛽 
plaque score is given by using Thal scoring system, this system has five phases which describes 
the progressive deposition of A𝛽. Phase 1 represents Aβ located in the neocortex, phase 2 shows 
amyloid in the allocortex or limbic areas, phase 3 is amyloid in the basal ganglia, phase 4 means 
amyloid is located in the brainstem or midbrain, and phase 5 represents amyloid in the 
cerebellum. Braak stages are used to describe the degree and positioning of NFTs in the brain. 





There are six stages Braak stages I/II represent NFTs located in the entorhinal cortex and regions 
near it, stages III/IIV represent NFTs in the hippocampus and amygdala, and stages V/VI 
represent NFTs distributed around the neocortex, affecting primary motor and sensory areas 
(Braak and Braak, 1991).  Another major component in AD pathology are neuritic plaques, 
which are extracellular deposits of aβ peptides. To characterize aβ plaques and rank the density 
of them, there is a scoring system developed by Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD score) (Mirra, 1991). These three scoring systems are known as 
the “ABC score” and are used to establish a definitive diagnosis of AD. Because this information 
can only be obtained in post-mortem brains, AD cannot be diagnosed with certainty in living 
people.  
In this study, post-mortem brains were used to examine the structural changes associated 
with AD using ex-vivo MRI. The goal was to find correlations between ex-vivo MRI data and 
neuropathological findings in later stage of AD.  As we know, brain atrophy is a strong indicator 
of dementia. Therefore, we hypothesize that demented patients would have greater atrophy 
compared to non-demented patients.  
 
Materials and Methods: 
Human subjects 
This study included 80 participants from individuals who were a part of the Adult in 
Changes (ACT) cohort or University of Washington Alzheimer’s Disease Center (ADRC) 
cohort. The study was approved by the University of Washington Human Subjects Committee. A 
total of 80 patients participated in this study (Table 1). 42 patients (52.5%) were diagnosed with 
dementia and 38 patients (47.4%) were diagnosed as not demented.  All subjects were 





diagnostically evaluated by a board-certified neuropathologist. The diagnostic evaluation 
included assignments of an “ABC” score and designation of AD neuropathological  
change, which followed the NIA-AA guidelines (Hyman et al. 2012). The subjects’ age, sex, 
region of examination, and diagnosis were all recorded (Table 1). 
 
Table 1. The demographics, region examined, and diagnosis of the patient of subject (n = 80). 
Individuals that are “not demented” and are diagnosed with the one of the three diseases occurs 
because having the disease does not necessarily cause dementia. Dementia is a clinical 
syndrome, while AD, LBD and VBI are neuropathological diagnoses. Individuals with “no 
diagnosis” were diagnosed with having any neuropathological disease.  
 
 Demented Patients (n=42) Not Demented Patients (n=38) 
Age (yrs.) 88.5 ± 9.7 90.3 ± 6.3 
% of Males 33.33% 42.11% 
Right  22 18 
Left 17 11 
Whole 3 9 
% with Alzheimer’s Disease 40.4% 25.6% 
% with Vascular Brain Injury 4.8% 2.6% 
% with Lewy Body 50.0% 25.6% 
% with No Diagnosis 2.4% 38.5% 





Neuroimaging: Structural MRI  
 
MRI scans were obtained from formalin-fixed brains by using an individual’s left, right, 
or both sides of the brain hemisphere. The right or left hemisphere was chosen at random, unless 
one hemisphere had visible lesions or hemorrhages. MRI’s were taken with 7T Siemens 
Magnetom MRI scanner using custom-built head coil. Then, the specimens were scanned on a 
3T Siemens Tim Trio with a 32-channel head coil. The images were manipulated by using a 
program called FreeSurfer, it is a software that allows us to produce computerized models of the 
brains using MRI data. FreeSurfer, when used for the analysis of structural MRIs, it has the 
ability to provide gray-white matter segmentation, reconstruct the cortical surface, and label 
regions on the cortical and subcortical structures (Figure 2A). In this study, FreeSurfer provided 
us with measurements of regional volume. The regions that were analyzed were the cerebral 
cortex, including both gray and white matter in the entorhinal, parahippocampal, fusiform, 
inferior temporal, middle temporal, superior temporal, caudal middle frontal, rostral middle 
frontal, and lateral occipital gyri, insula, hippocampus, and amygdala. (Figure 2B). 
 
A      





 B  
Figure 2. Overview of FreeSurfer software and its functions such as volumetric labelling, surface 
extraction, intensity normalization, gyral labeling, surface atlas registration, white matter 
segmentation, and skull stripping [A]. Free Surfer’s ability to label the different regions in the 
brain and regions that were used in our experiment [B]. 
 
Statistical Analysis: Mann-Whitney U Test 
 The statistical analyses were performed with Social Science Statistics. Utilizing a Mann-
Whitney U test because the data was not normally distributed. This statistical test was used to 
compare the effects of this neurodegenerative disease on regional volumes. If the sample we 
were examining was from the left hemisphere, then all the volumes used to normalize were from 
the left hemisphere and the same was done for the right hemisphere. If it was a whole brain 
sample, then we would add the volume from the right and the volume from the left and divide it 
by the sum of the right hemisphere and left hemisphere cerebral cortex and white matter, then 
divide that all by 2. 






Atrophy in gray and white matter of brain hemispheres  
We first sought to quantitatively examine the atrophy in the brain and its regions in 
demented and non-demented group. We used 22 right-side, 17 left-side, and 3 whole brains for 
demented patients and 18 right-side, 11 left-side, and 9 whole brains for not demented patients.  
To understand the relationship between dementia and its effects on atrophy, we first 
looked at the volume of the cerebral cortex and subcortical white matter. The mean volume of 
cerebral cortex per hemisphere for demented patients was 193.4± 4.7 𝑐𝑚3 and 219.2± 3.3 𝑐𝑚3 
for not demented patients (Figure 3A). To see if there was a normal distribution amongst the 
data, we used a Kolmogorov-Smirnov test. The data showed that it did not follow normal 
distribution (P = 0.68576). Volume in the cerebral cortex was significantly less in demented 
patients compared to not demented patients (Mann Whitney-U, P = <0.00001). Then, we looked 
at the sum of the cortex and subcortical white matter. The average value for demented was 
366.3± 7.1 𝑐𝑚3 and 411.2 ± 6.5𝑐𝑚3 for not demented (Figure 3B). The volume in demented 





























Figure 3. The average cerebral cortex volume [A] and the average sum of cerebral cortex plus 
white matter [B] between demented (blue) and not demented (grey) patients (n=80). 
Atrophy in regions in the limbic system 
The limbic system is responsible for emotions and memory, therefore we examined 
volumes of regions in the limbic system like the amygdala, entorhinal cortex, hippocampus, and 
parahippocampal gyrus between demented and non-demented patients. (Figure 4A).  Although 
the volumes in the amygdala appeared to be different, there was not a statistical difference 
between the two groups (P = 0.18352). The other regions in the limbic system were significantly 
different: P = 0.00128 in the entorhinal cortex, P = 0.03236 in the parahippocampal gyrus, and P 
= 0.00188 in the hippocampus. 
 
Atrophy in other regions of frontal, temporal and occipital lobe 
We examined other regions, such as insula, fusiform, inferior temporal, middle temporal, 



























(Figure 4B). The average volume for the fusiform gyrus was 6.476 and 8.210, the insula was 
6.321 and 7.173, the inferior temporal was 7.958 and 9.830, the middle temporal was 8.474 and 
9.988, the superior temporal was 9.776 and 11.561, the caudal middle frontal was 5.141 and 
5.442, and the lateral occipital was 10.216 and 11.520.  The volumes of caudal middle frontal 
gyrus showed no significant difference between the two groups (P = 0.18352). All other regions 
showed a significant difference: P = < 0.0001 in the fusiform gyrus, P = 0.00094 in the insula, P 
= 0.0001 in the inferior temporal, P = 0.0002 in the middle temporal, P = 0.003 in the superior 
























Demented Patient Not Demented Patient






Figure 4. Volumes of regions in the limbic system and four lobes. Comparisons between regional 
volumes between demented (blue) and not demented (grey) patients (n=80). 
The difference in volume between left and right hemisphere  
Of the 80 participants, data from both hemispheres was only available for 12 participants. 
The rest of the MRI data came from one hemisphere of the brain: 28 from the left hemisphere 
and 40 from the right hemisphere. Regardless of which hemisphere was being examined, we still 
wanted to see the relationship between atrophy and dementia. First, we wanted to compare the 
overall size of the right hemisphere versus the left hemisphere (Figure 5). The left hemisphere’s 
average volume was 210.15± 4.0𝑐𝑚3  and the right hemisphere’s average volume was 
203.33± 4.8𝑐𝑚3.  The left hemisphere appeared larger but was not significantly larger than the 

























Demented Patient Not Demented Patient







Figure 5. The average sum of the cerebral cortex and white matter volume between the right 
hemisphere (blue) and left (grey) hemisphere (n=80). 
 
Next, we looked at the hemispheres separately. Both the right and left hemisphere 
samples showed a significant difference between demented and not demented patients (P = 
0.0394). The right hemisphere had an average volume of 215.7± 4.8 𝑐𝑚3 for not demented and 
209.1± 4.0 𝑐𝑚3 for demented with a p-value of 0.04 (Figure 6A). The volume of the left 
hemisphere was 219.243 𝑐𝑚3 for not demented and 202.796 𝑐𝑚3 for demented patients with a p-
value that is less than 0.0001 (Figure 6B). Overall, we saw that there was a significant difference 






























Figure 6. The average volume of right hemisphere including the right hemisphere-only of 
whole brain samples between demented (blue) and not demented (grey) patients (n=50) [A]. The 
average volume of sum of left hemisphere and left sample of whole hemisphere between 










































Regions in limbic systems and regions in other lobes in both hemisphere 
As shown in Figure 8A, the average volume for the amygdala was 1.235 and 1.368, the 
entorhinal cortex was 1.445 and 1.439, the parahippocampal was 1.999 and 1.869 and the 
hippocampus was 3.977 and 4.005 in the right-hemisphere brains. The volumes of limbic regions 
in the right hemisphere were significantly different: P = 0.00758 in the amygdala, P = 0.03486 in 
the entorhinal cortex, P = 0.03156 int the parahippocampal gyri, and P = 0.0038 in the 
hippocampus. The average volume for the fusiform was 5.967 and 7.952, the insula was 5.983 
and 7.092, the inferior temporal was 7.123 and 9.420, the middle temporal was 8.315 and 
10.504, the superior temporal was 9.147 and 11.188, the caudal middle frontal was 4.992 and 
5.413, the rostral middle frontal was 13.644 and 16.015, and the lateral occipital was 9.864 and 
11.637. (*the 1st t value for averages is demented volume and the 2nd value is not demented volume). Patients’ 
caudal middle frontal region showed no significant difference when stratified by dementia 
diagnosis (P = 0.12114). In all other regions there was statistical difference: P = 0.00094 in the 
insula,  P = <0.00001 in the fusiform, P = 0.00094 in the middle temporal, P = 0.0005 in the 
superior temporal, P = 0.00262 in the rostral middle frontal, and P = 0.00168 in the lateral 
occipital gyrus.   
Lastly, in the left hemisphere most comparisons did not yield statistically significant 
differences. In the regions of the limbic system, we saw a similar trend between volumes, but 
they were not significant (Figure 10). In the left hemisphere, average volume for the amygdala 
was 1.196 and 1.289, the entorhinal was 1.417 and 1.582, the parahippocampal was 1.701 and 
1.852 and the hippocampus was 3.640 and 3.978 (4B). The p-values for those regions were: P = 
0.28914 in amygdala, P = 0.39824 in entorhinal cortex, P = 0.2672 in the parahippocampal 
gyrus, and P = 0.28914 in the hippocampus. The average volume for the fusiform was 7.495 and 





8.422, the insula was 6.841 and 7.150, the inferior temporal was 8.916 and 10.238, the middle 
temporal was 8.865 and 10.085, the superior temporal was 10.888 and 12.171,the caudal middle 
frontal was 5.605 and 5.582, the rostral middle frontal 14.269 and 15.471,and the lateral occipital 
was 10.979 and 11.461. The regions that showed statistical differences were:  P = 0.02202 in the 
fusiform, P = 0.00988 in the inferior temporal gyrus, P = 0.03236 in the middle temporal gyrus, 
and P = 0.0601 in the superior temporal gyrus. The insula had a p-value of 0.34722), P = 0.89656 
in the caudal middle frontal gyrus, P = 0.14706 in the rostral middle frontal gyrus, (P= 0.14706), 
and P = 0.25848)  in the lateral occipital gyrus. The regions showed no significant difference 
between demented and not demented patients in the left hemisphere. 























































































Figure 7. The volumes of regions in the limbic system in the right hemisphere between demented 
(blue) and not demented (grey) patients (n=50).  
Discussion: 
AD is continually being studied with the goal of finding ways for early diagnosis, 
preventative measures, and a cure for this and progressive disease, that is currently irreversible. 
AD has already affected so many people and will continue to affect millions more. Modern 
science and medicine have made advances in mitigating the symptoms of AD in early stages, but 
the search for a cure continues. The aim of this study was to use structural MRIs in post-mortem 
brains to determine if demented patients experience more atrophy in regions in the frontal, 
temporal, parietal, and occipital lobes compared to not demented patients, which would be 
consistent with findings from previous in vivo brain imaging data.  
 
Atrophy in the brain and its lobes 
Our results showed that both gray and white matter showed significantly more atrophy in 




























indictors that there is a loss of neuronal bodies as well as processes, resulting in loss of synaptic 
communication.  
Both hemispheres are roughly similar in size, but in most individuals the left hemisphere 
is slightly larger than the right hemisphere. Our findings showed that when comparing left 
hemisphere post-mortem brains samples to right hemisphere post-mortem brain samples the left 
hemisphere tended to be larger, but not significantly in all patients.   
 The temporal lobe is responsible for memory formation, storage, and processing, which is 
commonly impaired in AD patients. The temporal lobe is a region that is greatly affected by AD 
starting in the earliest stages of AD. The size of temporal lobe gyri, such as middle temporal, 
inferior temporal, superior temporal, and fusiform gyrus, were found to be significantly different 
between demented and non-demented subjects in the current study, which is in agreement with 
previous studies (Visser et al 2002).  Amygdala, one of subcortical structures associated with 
temporal cortex did not a show a significant difference in size between demented and non-
demented patients (Figure 4A), which is in contrast with previous studies. However, other 
subcortical temporal lobe structures such as hippocampus, parahippocampal gyrus, and 
entorhinal cortex all showed significant differences; these three regions play a major role in 
memory.  
The frontal lobe is responsible for higher level executive functions, expressive language, 
and movement. The caudal middle frontal gyrus showed no significant difference in demented vs 
non-demented subjects. The other region in the frontal lobe, the rostral middle frontal gyrus 
showed a significant difference.  The frontal lobe experiences atrophy in later stages of 
Alzheimer’s disease (Scahill et al. 2002), but it is not present in early stages. Another form of 
dementia called frontotemporal dementia is known to preferentially affect frontal lobes and 





temporal lobes. Atrophy in those regions are distinctive indication of frontotemporal dementia, 
while atrophy in the temporal lobe and hippocampal formation is more typical of AD (Frisoni 
1996).  
The primary function of the occipital lobe is visual processing. The lateral occipital gyrus 
is a region that is responsible for object recognition (Grill-Spector et al. 2001). This region has 
been shown to undergo atrophy in AD patients in late stages of the disease (Yang et. al 2019). 
Similar to other studies, when compared to non-demented patients, demented patients showed a 
significantly reduced cortical volume in this region. It has been observed previously that there is 
a correlation between the atrophy in the occipital lobe and AD when an individual is 
experiencing visual hallucinations as a symptom (Holoroyd 2000).  
Lastly, the insula showed significant decrease in cortical volume in demented patients, 
which has also been shown in living subjects (Sulimar et al. 2009). Atrophy in the insula have 
been related with apathy severity in neurodegenerative diseases including as AD (Belkhiria et al. 
2020). Apathy is a common symptom in patients with AD (Landes et al. 2001). While, damage 
where the insula is linked to apathy, this is a region that is also critical for a wide variety of other 
functions from sensory and affective processing to high-level cognition. These functions carried 
out by the insular cortex is related to symptoms experienced in AD (Uddin et al 2017).  
Overall, we found that the effect of dementia on cortical atrophy in post-mortem brains is 
congruent with findings reported in-vivo studies (Slumier et al. 2009). The one finding that was 
in contrast to other studies is the absence of significant atrophy in the amygdala, which was 
unexpected because many similar studies have found that the atrophy of the amygdala appears in 
the early stage of AD (Cuénod et al 1993).  
 





Inter-hemispheric differences in atrophy 
 The four lobes perform slightly different functions depending on the hemisphere. We 
evaluated cortical atrophy in the corresponding regions of both hemispheres, comparing the left 
hemisphere samples to the right hemisphere samples. In post-mortem brain samples, the right 
hemisphere showed significant differences associated with dementia in all regions except the 
caudal middle frontal gyrus. The regions that showed significant differences in volume between 
demented and not-demented patients were the fusiform, inferior temporal, middle temporal, and 
superior temporal gyri.  As expected, these were the regions located in the temporal lobe which 
has shown to be the most effected in AD. 
 
Limitations 
This study has several potential limitations. The number of left hemisphere samples was 
only 20 demented and 20 non-demented patients. To get a better understanding of ex-vivo 
imaging data trends between hemispheres, performing another study with a larger sample size 
will be helpful, as it will increase the statistical power and provide a clearer result. Additionally, 
the current study did not include many healthy and young brain samples. Adding samples from 
younger individuals as well as healthy controls will provide more complete dataset and will 
allow to assess age-related changes as well as provide a better understanding of disease-related 
trends.  
Another limitation of this study is that the brains were imaged after removed from the 
skull, which may have distorted the shape of atrophic brains more than unaffected brains and 
affected the results. Lastly when analyzing the data, we did not have the ante-mortem MRI data, 
so we were unable able to compare it to our post-mortem data set.  






Implications of this study, conclusions and future directions 
The goal of this study was to compare the volumes of various brain regions in demented and 
non-demented patients using ex-vivo MRI, and also compare the ex-vivo data with in vivo data 
from other studies. We report, that the volume of the brain and its regions showed trends similar 
to ones observed in living people. The findings in temporal, occipital, frontal, and the parietal 
lobe were consistent with previous observations that demented patients experience more atrophy. 
As expected, the atrophy in the temporal lobe was prominent across all AD stages.  A major 
difference in our findings compared to previous in vivo studies is that we did not observe a 
significant difference in the volume of the amygdala between demented and non-demented 
patients. Previous studies showed atrophy in amygdala in the earliest clinical stages of AD 
(Poulin et al 2012).  
. Because AD is a progressive, the brain changes a lot over time. Studies have shown that AD 
begins years before the symptoms of dementia appear, therefore using structural MRIs and 
monitoring atrophy of regions will help with early diagnosis. Early diagnosis is very important 
because not only does this allow the individual and others around them prepare for it, but it 
allows doctors to help treat the symptoms in the early stages hoping to slow down the disease.  
Studying post-mortem brains provides information about the structure and pathology of the 
diseased brain and allows to better understand the disease pathology and progression. When the 
individual is diagnosed while living, this diagnosis is based on the different tests and techniques, 
but it is the patient is stilled considered “probable AD” or “possible AD”. The diagnosis can only 
be confirmed at autopsy, and definitive correlations the MRI findings can only be made post-
mortem.   





 The number of cases of AD is projected to increase over the years. Early diagnosis and 
preventative measures for AD are critical. Using structural imaging in post-mortem brains will 
help us understand how cortical atrophy in AD correlates with clinical symptoms and 
neuropathological findings.  This study mostly focused on late stage of AD, because it is the final 
stage of AD preceding death and such brains are most abundant in brain banks established to 
study neurodegeneration. Further studies are needed to study the mild and moderate stage of AD, 
because therapeutic interventions are more likely to succeed when applied early in the diseased 
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